Radiotherapeutic agents: properties, dosimetry, and radiobiologic considerations.
Radioactive nuclides for treatment have occupied an important but somewhat diminishing role in the total practice of nuclear medicine. Although theoretically they should have important potentialities, particularly in the treatment of various forms of cancer, their development in this field has not kept pace with the progress in other treatment modalities in radiation oncology. Indications for the selection of appropriate isotopes for therapy revolve about the emission of beta particles of sufficient energy, which are administered in a chemical form that reaches the tumor. Methods of calculation of doses delivered to sites of deposition are discussed in the text. Radiobiologic considerations include the possibility of early deleterious effects from overdosage, and consideration of chromosomal changes of circulating lymphocytes and their implications. Late effects that have been of great public concern are confined almost solely to possible carcinogenesis, and this effect has been minimal in patients receiving therapeutic levels of radioactive drugs. Genetic and developmental effects, also, have been negligible. Complications encountered more frequently have been leukemia after extensive therapy of thyroid carcinoma, and local fibrosis after direct injection of radioactive colloids into tumor tissue.
D000293:Adolescent; D000328:Adult; D000818:Animals; D002875:Chromosomes / Q000187:drug effects; D004583:Electrons; D005260:Female; D005500:Follow-Up Studies; D005720:Gamma Rays; D006207:Half-Life; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D007953:Leukemia, Radiation-Induced / Q000209:etiology; D008297:Male; D011247:Pregnancy; D011829:Radiation Dosage; D011868:Radioisotopes / Q000627:therapeutic use*; D011878:Radiotherapy / Q000009:adverse effects / Q000379:methods*; D014517:Ureteral Obstruction / Q000209:etiology
D007457:Iodine Radioisotopes; D011868:Radioisotopes